NASDAQ:ALDR - Alder BioPharmaceuticals, Inc.
$10.30
 $0.48
+4.89%
4:00PM EDT
2019-07-22
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ALDR     avg for
industry  
  avg for
sector  
42 stocks weight:  31. 68   0. 00   0. 00  
42 stocks rank:  2. 90 K 1. 35 K 799. 74  
# analyst opinions:  14. 00   12. 76   13. 14  
mean recommendation:  2. 20   2. 11   2. 07  

quick ratio:  7. 88   5. 61   1. 85  
current ratio:  8. 34   6. 00   2. 31  

target price low:  9. 00   75. 88   108. 31  
target price avg:  11. 46   97. 27   130. 10  
target price high:  20. 64   124. 58   149. 02  
1-yr high:  19. 90   104. 89   135. 09  
last close:  10. 30   79. 79   118. 76  
50-day avg:  11. 22   79. 39   116. 18  
200-day avg:  12. 48   81. 61   114. 52  
1-yr low:  9. 80   62. 76   94. 70  
volume:  984. 34 K 2. 99 M 4. 43 M
50-day avg volume:  886. 34 K 3. 39 M 4. 22 M
200-day avg volume:  969. 23 K 3. 13 M 4. 83 M

1-day return:  4. 89 % 0. 33 % 0. 14 %
this week return:  4. 89 % 0. 33 % 0. 14 %
12-wk return:  -16. 12 % 1. 00 % 3. 51 %
52-wk return:  -45. 35 % 0. 58 % 10. 25 %

enterprise value (EV):  639. 55 M 44. 78 B 115. 63 B
market cap:  902. 16 M 38. 01 B 103. 29 B
EBITDA:  -337. 77 M 4. 47 B 7. 73 B
enterprise multiple (EV/EBITDA):  -1. 89   2. 11   11. 26  
total debt:  190. 41 M 11. 72 B 16. 76 B
debt/equity:  73. 01   61. 22   124. 43  
net income (common):  -333. 60 M 2. 06 B 3. 79 B

shares outstanding:  67. 84 M 562. 08 M 1. 27 B
shares:  69. 78 M 573. 33 M 1. 26 B
shares short:  15. 40 M 11. 60 M 12. 29 M
shares short prior month:  13. 52 M 9. 81 M 12. 46 M
short ratio:  16. 27   5. 88   3. 41  
short % of float:  24. 95 % 6. 88 % 2. 72 %
total cash/share:  5. 68   10. 62   8. 83  
total cash:  474. 62 M 6. 17 B 5. 72 B
free cash flow:  -171. 95 M 3. 08 B 3. 10 B
operating cash flow:  -251. 33 M 3. 99 B 4. 08 B

book value:  1. 89   12. 74   26. 25  
price/book:  5. 46   4. 38   9. 01  
gross profits:  -161. 99 M 7. 93 B 35. 64 B
operating margins:  0. 00 % -319. 65 % -29. 05 %
EBITDA margins:  0. 00 % 11. 82 % 24. 13 %
profit margins:  0. 00 % 5. 62 % 14. 29 %
gross margins:  0. 00 % 34. 75 % 57. 07 %

1-yr max volatility:  17. 64 % --- ---
1-yr mean volatility:  2. 71 % 1. 95 % 1. 25 %

1-yr EPS:  -4. 81   1. 58   3. 82  
forward EPS:  -3. 18   3. 16   6. 65  
P/E:  -2. 14   0. 21   31. 97  
forward P/E:  -3. 09   4. 95   15. 14  
PE/G:  0. 08   0. 74   0. 13  
growth:  -27. 10 % 295. 81 % 85. 47 %
earnings high:  -0. 68   0. 84   1. 56  
earnings avg:  -0. 94   0. 65   1. 45  
earnings low:  -1. 37   0. 40   1. 35  
revenue high:  -0. 00   2. 70 B 8. 76 B
revenue avg:  -0. 00   2. 64 B 8. 62 B
revenue low:  -0. 00   2. 58 B 8. 45 B
return on assets:  -38. 21 % -3. 43 % 4. 51 %
return on equity:  -99. 05 % -104. 30 % 140. 44 %

beta (1yr vs S&P500):  1. 79   1. 27   0. 91  
sharpe (1yr):  -0. 67   0. 20   0. 80  

held % insiders:  5. 20 % 6. 63 % 3. 46 %
held % institutions:  101. 40 % 76. 45 % 67. 87 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-22 : ALDR
.    112.634 =       112.634 :: --> INITIAL WEIGHT <--
.    - 4.807 =       107.827 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.701 =       291.204 :: P/E factor
.    x 1.886 =       549.174 :: PE/G factor
.      x 1.5 =       823.879 :: beta factor
.    x 0.881 =       725.741 :: sharpe factor
.    x 2.611 =      1895.044 :: current ratio factor
.     x 1.07 =      2028.169 :: quick ratio factor
.     x 1.03 =      2089.569 :: short ratio factor
.    x 1.067 =      2229.597 :: price-to-book factor
.    x 1.344 =       2997.52 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.759 =      8270.862 :: sector+industry 1-year gains factor
.     x 1.01 =      8353.447 :: industry 12-weeks return factor
.    x 1.309 =     10937.723 :: industry 2-weeks return factor
.    x 0.904 =      9886.926 :: company one-year gains+dividend factor
.    x 1.997 =     19747.945 :: company 13 weeks' performance factor
.    x 0.962 =     18991.977 :: "drift" penalty 1 days ago
.    x 0.982 =     18655.907 :: "drift" penalty 3 days ago
.    x 0.981 =     18301.297 :: "drift" penalty 4 days ago
.    x 0.991 =     18133.338 :: "drift" penalty 5 days ago
.    / 1.993 =      9097.991 :: overall "drift" factor
.     x 0.91 =      8283.215 :: largest single-day jump factor
.    x 0.145 =      1203.956 :: low price factor
.    x 1.422 =      1712.079 :: notable returns + performance factor
.    x 3.438 =      5886.415 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.    x 0.692 =      4073.084 :: forward EPS factor
.    x 0.888 =      3617.141 :: forward P/E factor
.    x 1.184 =       4282.55 :: industry recommendation factor
.    x 1.927 =      8251.325 :: company recommendation factor
.    x 1.002 =      8263.862 :: factor historical industry gain for week 29
.    x 0.946 =      7815.791 :: target low factor
.    x 1.112 =      8689.776 :: target mean factor
.    x 1.042 =      9055.454 :: target high factor
.    x 5.084 =     46034.653 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        14.648 :: reduced for readability
.   + 17.037 =        31.685 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     31.685 :: FINAL WEIGHT for NASDAQ:ALDR


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org